- Ambry Genetics' CARE Program validated with 99.5% accuracy for hereditary cancer risk assessment.
- The study published in the Journal of the National Comprehensive Cancer Network highlights CARE's effectiveness.
- Ambry Genetics' parent company, Tempus AI, Inc. (TEM, Financial), advances precision medicine through AI.
Ambry Genetics, a subsidiary of Tempus AI, Inc. (TEM), has announced that its AmbryCARE Program® (CARE) successfully validated its accuracy in identifying high-risk patients for hereditary cancer through a peer-reviewed study. The study, published in the Journal of the National Comprehensive Cancer Network, demonstrated the tool's ability to interpret the NCCN Clinical Practice Guidelines with an impressive accuracy of 99.5%. This validation confirms CARE’s effectiveness as a digital risk assessment tool in identifying patients who can benefit from genetic testing and personalized care.
Approximately 5% of individuals carry a mutation in a cancer predisposition gene, yet most remain unaware. Given the complexity and frequent updates of the NCCN Guidelines®, health systems could face challenges in their application. The CARE program is designed to streamline hereditary cancer risk assessments, allowing non-specialist clinicians to identify eligible patients accurately and efficiently.
Dr. Dax Kurbegov, Vice President and Physician-In-Chief at HCA Healthcare’s Sarah Cannon Cancer Network, stated that CARE's accuracy emphasizes its reliability in identifying patients who require genetic services, allowing healthcare providers to scale hereditary cancer risk assessments confidently within community hospitals.
Tom Schoenherr, CEO of Ambry Genetics, noted that CARE offers an end-to-end solution that transforms how genetic testing is implemented and scaled within healthcare systems. By collecting thorough medical histories and providing accurate risk assessments, clinicians can expand access to genetic services, leading to improved patient outcomes and seamless integration into patient care strategies.
Ambry Genetics, known for its leadership in clinical genomic testing, continues to improve health outcomes by translating scientific research into clinically actionable results. Its parent company, Tempus AI, Inc., is committed to advancing precision medicine through its extensive library of multimodal data and AI-enabled solutions.
